• 1
    von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999; 17: 658667.
  • 2
    Sekido Y, Obata Y, Ueda R, et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res. 1999; 51: 24162419.
  • 3
    Potti A, Moazzam N, Ramar K, Hanekom DS, Kargas S, Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol. 2003; 14: 894897.
  • 4
    Naeem M, Dahiya M, Clark JI, Creech SD, Alkan S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol. 2002; 33: 11821187.
  • 5
    Micke P, Basrai M, Faldum A, et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res. 2003; 9: 188194.
  • 6
    Blackhall FH, Pintilie M, Michael M, et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res. 2003; 9: 22412247.
  • 7
    Boldrini L, Ursino S, Gisfredi S, et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res. 2004; 10(12 Pt 1): 41014108.
  • 8
    Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res. 1996; 56: 370376.
  • 9
    Heinrich M, Griffith D, Druker B, Wait C, Ott K, Zigler A. Inhibition of c-kit receptor tyrosine kinase activity by STI-571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925932.
  • 10
    Heinrich MC, Blanke CD, Druker BJ, Corless CL. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol. 2002; 20: 16921703.
  • 11
    Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347: 472480.
  • 12
    Wang WL, Healy ME, Sattler M, et al. Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571. Oncogene. 2000; 19: 35213528.
  • 13
    Krystal GW, Honsawek S, Litz J, Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res. 2000; 6: 33193326.
  • 14
    Johnson BE, Fischer T, Fischer B, et al. Phase II study of imatinib in patients with small cell lung cancer. Clin Cancer Res. 2003; 9(16 Pt 1): 58805887.
  • 15
    Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003; 21: 43424349.
  • 16
    Burger H, den Bakker MA, Stoter G, Verweij J, Nooter K. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer. 2003; 39: 793799.
  • 17
    Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL Jr. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res. 2004; 10: 35283534.
  • 18
    Heinrich MC. Is KIT an important therapeutic target in small cell lung cancer? Clin Cancer Res. 2003; 9: 58255828.
  • 19
    Johnson FM, Tran HT, Johanson MJ, et al. Phase I trial of imatinib mesylate, cisplatin, and irinotecan in small cell lung cancer. Lung Cancer. 2004; 46(Supp 1): S4445.